23andMe Holding Co. (ME) Return on Equity (ROE): -721.75%
Is 23andMe Holding Co.’s return on equity (ROE) high or low?
23andMe Holding Co.'s return on equity (ROE) of -721.75% is 1282% below its 5-year average of 61.09%, near the low end of its 5-year range (-721.75%–1050.35%).
As of Monday, June 15, 2026. 307.19% below its 12-month average of 348.35%.
ME Return on Equity (ROE) Chart
ME Average Return on Equity (ROE) Chart
ME Current vs Average Return on Equity (ROE) Chart
ME Return on Equity (ROE) Metrics
RETURN ON EQUITY (ROE)
-721.75%
RETURN ON EQUITY (ROE) AVG TTM
348.35%
RETURN ON EQUITY (ROE) AVG 3Y
157.32%
RETURN ON EQUITY (ROE) AVG 5Y
61.09%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
-307.19%
CURRENT VS 3Y AVG
-558.76%
CURRENT VS 5Y AVG
-1281.52%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
ME Competitors' Return on Equity (ROE)
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| 23andMe Holding Co. (ME) | $15.31M | -721.75% | 348.35% | 157.32% | 61.09% |
| DENTSPLY SIRONA Inc. (XRAY)vs › | $2.02B | -47.65% | -45.75% | -30.11% | -18.95% |
| Hims & Hers Health, Inc. (HIMS)vs › | $5.98B | -2.97% | 25.09% | 5.57% | 0.40% |
| Bio-Rad Laboratories, Inc. (BIO)vs › | $7.73B | 2.46% | -8.94% | -15.72% | 1.14% |
| Tempus AI, Inc. (TEM)vs › | $8.35B | -72.74% | -651.33% | -315.37% | -198.08% |
| Charles River Laboratories International, Inc. (CRL)vs › | $9.03B | -6.28% | -2.13% | 6.32% | 9.65% |
| Walgreens Boots Alliance, Inc. (WBA)vs › | $10.37B | -87.68% | -49.03% | -18.16% | -9.00% |
| Baxter International Inc. (BAX)vs › | $10.77B | -18.17% | -12.46% | -8.76% | -1.37% |
| Align Technology, Inc. (ALGN)vs › | $12.52B | 10.36% | 10.54% | 10.84% | 19.93% |
| The Cooper Companies, Inc. (COO)vs › | $13.24B | 2.86% | 4.70% | 4.67% | 11.22% |
Return Analysis
ROE
-721.8%
ROA
-163.0%
23andMe Holding Co. Return on Equity (ROE) Formula & Definition
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
23andMe Holding Co. Return on Equity (ROE) FAQ
- What is the return on equity (ROE) for 23andMe Holding Co. (ME)?
- The return on equity (ROE) for ME stock is -721.75%.
- Is 23andMe Holding Co.'s return on equity (ROE) high or low?
- 23andMe Holding Co.'s return on equity (ROE) of -721.75% is 1282% below its 5-year average of 61.09%, near the low end of its 5-year range (-721.75%–1050.35%).
- What is the TTM average return on equity (ROE) for 23andMe Holding Co. (ME)?
- The TTM average return on equity (ROE) for ME stock is 348.35%.
- What is the 3Y average return on equity (ROE) for 23andMe Holding Co. (ME)?
- The 3Y average return on equity (ROE) for ME stock is 157.32%.
- What is the 5Y average return on equity (ROE) for 23andMe Holding Co. (ME)?
- The 5Y average return on equity (ROE) for ME stock is 61.09%.
23andMe Holding Co. Return on Equity (ROE) History
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2025-03-31 | 1050.35% |
| 2024-03-31 | -353.65% |
| 2023-03-31 | -43.65% |
| 2022-03-31 | -23.75% |
| 2021-03-31 | -75.85% |
| 2020-03-31 | -186.93% |
| 2019-03-31 | -58.49% |
Related Metrics
About 23andMe Holding Co.
23andMe Holding Co. is a prominent direct-to-consumer genetic testing firm, structured around two primary business units: Consumer & Research Services and Therapeutics. Through its Consumer & Research Services division, the company provides individuals with a comprehensive suite of genetic reports, derived from a simple saliva sample collected via their proprietary kit. These reports offer insights into customers' genetic ancestral origins, predispositions to certain personal health risks, the likelihood of being a carrier for rare conditions that could be passed to offspring, and how their genetic makeup might influence responses to various medications. The Therapeutics segment is dedicated to pharmaceutical research and development, focusing on the discovery and advancement of novel treatments aimed at improving patient well-being across diverse medical fields, including oncology, respiratory, and cardiovascular diseases. This segment also engages in the out-licensing of intellectual property associated with identified drug targets that are progressing through clinical development. 23andMe maintains a strategic partnership with GlaxoSmithKline Intellectual Property (No.3) Limited, leveraging genetic insights to validate, develop, and ultimately commercialize new pharmaceutical products. Established in 2006, the company's corporate headquarters are situated in South San Francisco, California.
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- Joseph Selsavage